The webinar takes place on Thursday, October 28 – you can register for free here to listen live or to access on-demand after the event.
Our speakers will put the spotlight on two very topical issues.
Scaling up mRNA production
mRNA vaccines have been the star when it comes to COVID-19 vaccine development: now all eyes are on the future of this technology.
Lucy Foley, Director of Biologics at the Centre for Process Innovation Limited (CPI), will take us through the process for mRNA manufacture: and the advantages and challenges as a platform technology.
She’ll also share what the CPI has learned over the last 18 months as it supports the scale-up of COVID-19 vaccine manufacturing.
IP waiver proposals
In October 2020, India and South Africa proposed a broad IP waiver on COVID-19 technologies. The idea behind the waiver was that countries would be able to take the tech and make their own vaccines locally. While the US government notably backed the proposals, others are not at all convinced that this will produce a single dose more.
Komal Kalha of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is the Federation’s Associate Director, Intellectual Property & Trade Policy, and she has been tracking the evolution of the proposals over the last year.
She'll give an overview of where COVID-19 vaccine production is today; explain why the industry does not support IP waivers; and outline what solutions the IFPMA supports instead.
